RU2002117537A - A method for treating the effects of tissue hypoxia in critically ill patients - Google Patents

A method for treating the effects of tissue hypoxia in critically ill patients

Info

Publication number
RU2002117537A
RU2002117537A RU2002117537/14A RU2002117537A RU2002117537A RU 2002117537 A RU2002117537 A RU 2002117537A RU 2002117537/14 A RU2002117537/14 A RU 2002117537/14A RU 2002117537 A RU2002117537 A RU 2002117537A RU 2002117537 A RU2002117537 A RU 2002117537A
Authority
RU
Russia
Prior art keywords
treating
effects
critically ill
ill patients
tissue hypoxia
Prior art date
Application number
RU2002117537/14A
Other languages
Russian (ru)
Other versions
RU2226096C1 (en
Inventor
Георгий Александрович Ливанов
Виктор Васильевич Мороз
Баир Васильевич Батоциренов
Андрей Юрьевич Андрианов
Original Assignee
Санкт-Петербургский государственный научно-исследовательский институт скорой помощи им. И.И. Джанелидзе
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкт-Петербургский государственный научно-исследовательский институт скорой помощи им. И.И. Джанелидзе filed Critical Санкт-Петербургский государственный научно-исследовательский институт скорой помощи им. И.И. Джанелидзе
Priority to RU2002117537/14A priority Critical patent/RU2226096C1/en
Publication of RU2002117537A publication Critical patent/RU2002117537A/en
Application granted granted Critical
Publication of RU2226096C1 publication Critical patent/RU2226096C1/en

Links

Claims (1)

Способ лечения последствий тканевой гипоксии у пациентов в критическом состоянии, основанный на инфузионном введении реамберина, отличающийся тем, что за 1 час до инфузии реамберина вводят перфторан в дозе 5-7 мл/кг массы тела однодвухкратно с периодичностью в 24 ч.A method for treating the effects of tissue hypoxia in critically ill patients, based on the infusion of reamberin, characterized in that 1 hour before the infusion of reamberin, perftoran is administered at a dose of 5-7 ml / kg of body weight once twice with a frequency of 24 hours.
RU2002117537/14A 2002-07-01 2002-07-01 Method for treating hypoxia consequences in patients in critical state RU2226096C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2002117537/14A RU2226096C1 (en) 2002-07-01 2002-07-01 Method for treating hypoxia consequences in patients in critical state

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2002117537/14A RU2226096C1 (en) 2002-07-01 2002-07-01 Method for treating hypoxia consequences in patients in critical state

Publications (2)

Publication Number Publication Date
RU2002117537A true RU2002117537A (en) 2004-02-10
RU2226096C1 RU2226096C1 (en) 2004-03-27

Family

ID=32390520

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002117537/14A RU2226096C1 (en) 2002-07-01 2002-07-01 Method for treating hypoxia consequences in patients in critical state

Country Status (1)

Country Link
RU (1) RU2226096C1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373780A1 (en) 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP1853544A4 (en) 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
AU2008246305B2 (en) 2007-04-13 2013-03-21 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
ES2654945T3 (en) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Oral formulations of trans bipolar carotenoids
CN109152839A (en) 2016-03-24 2019-01-04 扩散药品有限公司 Purposes of the bipolarity trans-carotenoid together with chemotherapy and radiotherapy in treating cancer

Also Published As

Publication number Publication date
RU2226096C1 (en) 2004-03-27

Similar Documents

Publication Publication Date Title
MXPA05007857A (en) Indole-derivative modulators of steroid hormone nuclear receptors.
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
AU1249902A (en) Effective antitumour treatments
EA200400548A1 (en) TREATMENT OF HEAVY PNEUMONIA THROUGH THE INTRODUCTION OF THE TISSUE FACTOR INHIBITOR (TFPI)
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
NZ507203A (en) Use of dexmedetomidine for ICU sedation
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
EP1440689A3 (en) Treatment of neurotic disorders
RU2002117537A (en) A method for treating the effects of tissue hypoxia in critically ill patients
BR0009380A (en) Improved cancer treatment with temozozomide
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
FI20011464A0 (en) Combination therapy for the treatment of heart failure
RU2004112422A (en) ROUVASTATIN IN PREDEDENTIONAL CONDITIONS
DE60111622D1 (en) ISOLATED DOSE THERAPIES WITH VULNERABLE ACTIVITY
EP1622450A4 (en) Method for promoting uninterrupted sleep by administration of trospium chloride
WO2001007038A3 (en) Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
DE60235965D1 (en) COMBINATION OF LEVOSIMENDAN AND A CALCIUM SOURCE FOR THE TREATMENT OF HEART FAILURE
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
AU2003288107A1 (en) Tiotropium-containing medicament combinations used for inhaling
MXPA03010920A (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia.
RU2003125142A (en) METHOD OF PERFUOROAN USE
RU2000110690A (en) METHOD OF ANTIBIOTIC THERAPY
RU2002109357A (en) A method for the treatment of dysbiotic intestinal disorders in patients with pulmonary tuberculosis

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20040702